Anti Malarial Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Anti Malarial Drugs Market is Segmented by Drug Class (Aryl aminoalcohol compounds, Antifolate compounds, Artemisinin compounds and Other Drug Types), Malaria Type, Mechanism of Action and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: Middle-East and Africa
CAGR: 3.37 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The antimalarial drugs are used for the treatment and prevention of malaria infection. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and underdeveloped countries. According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 malaria-related deaths in 2017. Hence, the high prevalence of malaria is driving the growth of this market. 

The other factors includes the increase in awareness initiatives by governments and research for new anti-malarial drugs and therapies are also helping this market grow. However, side-effects of anti-malarial drugs and presence of counterfeit and substandard drugs are restraining the overall growth of this market.

Scope of the Report

As per the scope of the report, antimalarial drugs are the drugs that are designed to treat malaria in individuals or prevent the infection in individuals who have no immunity for the infection. The malaria is the disease caused due to the parasite known as Plasmodium, belongs to the organism group Protozoa. Generally, malaria is treated by the single drug therapy as a first line therapy, and sometimes the combination drug therapy is for the second line of infection. Anti-malarial drugs are available in the market in the form of tablet, injectables, and capsules.

By Drug Class
Aryl aminoalcohol compounds
Antifolate compounds
Artemisinin compounds
Other Drug Types
By Malaria Type
Plasmodium Falciparum
Plasmodium Vivax
Plasmodium Malariae
Plasmodium Ovale
By Mechanism of Action
Treatment for Malaria
Prevention from Malaria
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Artemisinin Compounds Segment is Expected to Register High Growth During the Forecast Period

The artemisinin-based compounds (ACTs) and the combination therapies (ACTs) for found to effective treatment being used for the treatment of uncomplicated malaria caused by the P. falciparum parasite. By combining 2 active ingredients with different mechanisms of action, ACTs are the most effective antimalarial medicines being currently available in the market. 

According to the WHO Report, they currently recommend 5 ACTs for use against P. falciparum malaria. However, the increasing consumption of artemisinin based compounds and monotherapies will help the overall growth of the market.


Middle East and Africa Holds a Large Share of the Market Growth During the Forecast Period

Middle East and Africa has been accounted for the major market share and is expected to continue this trend, owing to rapid surge in prevalence of malaria in the region. According to the World Health Organization (WHO), there were an estimated 228 million cases of malaria worldwide in 2018, out of which WHO African Region carried a disproportionately high share of the global malaria burden. Therefgore the Middle East and Africa region is expected to have one of the largest share in the total anti-malarial drugs market.

On the other side, Asia-Pacific is also estimated to register the fastest growth due to the increase in awareness regarding the use of antimalarial drugs for early diagnosis of the infection for better treatment.


Competitive Landscape

Majority of the anti-malarial drug are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany and Japan. Asia-pacific is also witnessing an emergence of some small players which has helped the market grow and increased the competitiveness.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries

      2. 4.2.2 Increasing Awareness Initiatives Undertaken by Government

      3. 4.2.3 Increasing Research for New Drugs and New Combinations Therapies

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Anti-malaria Drugs

      2. 4.3.2 Presence of Counterfeit and Substandard Antimalarial Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 Aryl aminoalcohol compounds

      2. 5.1.2 Antifolate compounds

      3. 5.1.3 Artemisinin compounds

      4. 5.1.4 Other Drug Types

    2. 5.2 By Malaria Type

      1. 5.2.1 Plasmodium Falciparum

      2. 5.2.2 Plasmodium Vivax

      3. 5.2.3 Plasmodium Malariae

      4. 5.2.4 Plasmodium Ovale

    3. 5.3 By Mechanism of Action

      1. 5.3.1 Treatment for Malaria

      2. 5.3.2 Prevention from Malaria

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Mylan N.V.

      2. 6.1.2 Cipla Limited

      3. 6.1.3 GlaxoSmithKline Plc

      4. 6.1.4 Novartis AG

      5. 6.1.5 F. Hoffmann-La Roche AG

      6. 6.1.6 Bayer AG

      7. 6.1.7 Lincoln Pharmaceuticals

      8. 6.1.8 Strides Pharma Science Limited

      9. 6.1.9 Glenmark Pharmaceuticals

      10. 6.1.10 Alliance Pharma PLC

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Anti Malarial Drugs Market market is studied from 2018 - 2026.

The Anti Malarial Drugs Market is growing at a CAGR of 3.37% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

Middle-East and Africa holds highest share in 2020.

Mylan N.V., F. Hoffmann-La Roche AG, Cipla, Novartis AG, GlaxoSmithKline PLC are the major companies operating in Anti Malarial Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!